Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

U. Platzbecker, P. Fenaux, L. Adès, A. Giagounidis, V. Santini, A. A. van de Loosdrecht, D. Bowen, T. de Witte, G. Garcia-Manero, E. Hellström-Lindberg, U. Germing, R. Stauder, L. Malcovati, Mikkael A. Sekeres, David P. Steensma, S. Gloaguen

Blood (2019) 133 (10): 1020–1030.

https://doi.org/10.1182/blood-2018-06-857102

Published: 2019

Journal Articles

Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study).

F. Merabet, N. Boissel, O. Reman, Jean-Henri Bourhis, B. Quesnel, S. Rigaudeau, C. Cordonnier, D. Bordessoule, H. Tilly, S. Corm, M. Michallet, J.M. Miclea, X. Thomas, S. Chevret, P. Fenaux, S. Castaigne

Blood (2007) 110 (11): 1857.

https://doi.org/10.1182/blood.V110.11.1857.1857

Published: 2007

Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Blood (2006) 108 (11): 522.

https://doi.org/10.1182/blood.V108.11.522.522

Published: 2006

Journal Articles

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

J. Tamburini, C. Elie, D. Vassilief, M.C. Quarre, O. Beyne-Rauzy, M. Gardembas, A. Aouba, C. Berthou, L. Sanhes, A. Guerci, A. Stamatoullas, F. Bauduer, J.J. Sotto, L. Legros, S. Vaultier, P. Fenaux, F. Dreyfus, D. Bouscary

Blood (2006) 108 (11): 2673.

https://doi.org/10.1182/blood.V108.11.2673.2673

Published: 2006

Journal Articles

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Blood (2005) 106 (11): 2537.

https://doi.org/10.1182/blood.V106.11.2537.2537

Published: 2005

Journal Articles

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

Blood (2005) 106 (11): 890.

https://doi.org/10.1182/blood.V106.11.890.890

Published: 2005

Journal Articles

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.

Blood (2005) 106 (11): 544.

https://doi.org/10.1182/blood.V106.11.544.544

Published: 2005

Journal Articles

Association between Vasculitides and Myelodysplastic Syndrome (MDS): A Report on 21 Cases.

O. Fain, M. Hamidou, P. Cacoub, B. Godeau, J. Stirnemann, L. Guillevin, P. Fenaux

Blood (2004) 104 (11): 4714.

https://doi.org/10.1182/blood.V104.11.4714.4714

Published: 2004

Journal Articles

Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS).

S. Brechignac, E. Hellstrom-Lindberg, D. T. Bowen, T. M. DeWitte, M. Cazzola, P. Fenaux

Blood (2004) 104 (11): 4716.

https://doi.org/10.1182/blood.V104.11.4716.4716

Published: 2004

Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD

Blood (2004) 104 (11): 1438.

https://doi.org/10.1182/blood.V104.11.1438.1438

Published: 2004

Journal Articles

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

Blood (2004) 104 (11): 391.

https://doi.org/10.1182/blood.V104.11.391.391

Published: 2004

Journal Articles

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

L. Mannone, C. Gardin, M.C. Quarre, J.F. Bernard, S. Giraudier, E. Rosenthal, D. Vassilief, F. Hamza, S. Park, J.J. Kiladjian, S. Vaultier, Mo Beyne-Rouzy, S. Cheze, L. Voilliat, P. Agape, F. Dreyfus, P. Fenaux

Blood (2004) 104 (11): 69.

https://doi.org/10.1182/blood.V104.11.69.69

Published: 2004

Journal Articles

Incidence, Clinical Features, and Outcome of All Trans -Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

Blood (1998) 92 (8): 2712–2718.

https://doi.org/10.1182/blood.V92.8.2712

Published: 1998

Journal Articles

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group

E Wattel, A Guerci, B Hecquet, T Economopoulos, A Copplestone, B Mahe, ME Couteaux, L Resegotti, V Voglova, C Foussard, B Pegourie, JL Michaux, E Deconinck, AM Stoppa, G Mufti, D Oscier, P Fenaux

Blood (1996) 88 (7): 2480–2487.

https://doi.org/10.1182/blood.V88.7.2480.bloodjournal8872480

Published: 1996

Journal Articles

Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes

FA Asimakopoulos, TL Holloway, EP Nacheva, MA Scott, P Fenaux, AR Green

Blood (1996) 87 (4): 1561–1570.

https://doi.org/10.1182/blood.V87.4.1561.bloodjournal8741561

Published: 1996

Journal Articles

All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]

L Degos, H Dombret, C Chomienne, MT Daniel, JM Miclea, C Chastang, S Castaigne, P Fenaux

Blood (1995) 85 (10): 2643–2653.

https://doi.org/10.1182/blood.V85.10.2643.bloodjournal85102643

Published: 1995

Journal Articles

p16 gene homozygous deletions in acute lymphoblastic leukemia

B Quesnel, C Preudhomme, N Philippe, M Vanrumbeke, I Dervite, JL Lai, F Bauters, E Wattel, P Fenaux

Blood (1995) 85 (3): 657–663.

https://doi.org/10.1182/blood.V85.3.657.bloodjournal853657

Published: 1995

Journal Articles

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

E Wattel, C Preudhomme, B Hecquet, M Vanrumbeke, B Quesnel, I Dervite, P Morel, P Fenaux

Blood (1994) 84 (9): 3148–3157.

https://doi.org/10.1182/blood.V84.9.3148.3148

Published: 1994

Journal Articles

Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter]

P Fenaux, E Wattel, E Archimbaud, M Sanz, B Hecquet, N Fegueux, A Guerci, H Link, M Fey, S Castaigne

Blood (1994) 84 (2): 666–667.

https://doi.org/10.1182/blood.V84.2.666.666

Published: 1994

Journal Articles

Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells

C Dubois, MH Schlageter, A de Gentile, F Guidez, N Balitrand, ME Toubert, I Krawice, P Fenaux, S Castaigne, Y Najean

Blood (1994) 83 (11): 3264–3270.

https://doi.org/10.1182/blood.V83.11.3264.3264

Published: 1994

NARROW

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study).

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.

Association between Vasculitides and Myelodysplastic Syndrome (MDS): A Report on 21 Cases.

Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS).

Thalidomide for the Treatment of Low Risk Myelodysplasia.

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study.

Incidence, Clinical Features, and Outcome of All Trans -Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group

Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes

All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia [see comments]

p16 gene homozygous deletions in acute lymphoblastic leukemia

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter]

Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only